Translate
Subscribe to Blog via Email
Ronny Allan
What is Nivolumab (Opdivo)
Nivolumab is a type of cancer treatment drug called an immunotherapy. It is a treatment for a number of different types of cancer. You might have it as part of a clinical trial for other types of cancer.
What is Temozolomide (Temodal)
Temozolomide is a type of chemotherapy. It is well known in Neuroendocrine Cancer as the TEM in CAPTEM
Trial Summary
The purpose of the trial. Treatment options are sometimes limited in patients with metastatic neuroendocrine neoplasms (NEN). The primary endpoint was response rate (using RECIST 1.1). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Immune profiling was performed by mass cytometry to evaluate the effect on peripheral blood immune cell subsets.
“In summary, the combination of temozolomide and nivolumab showed promising activity in NEN, especially in lung and pancreatic NEN. This study included patients with both NET and NEC and activity was seen across the spectrum of differentiation in NEN.
This study has several limitations, including its single-arm, single-institution nature (see link below Supplementary Table S5) with relatively short follow-up. The study population was also heterogeneous, and studies of patient subsets are limited because of small numbers. Biomarker studies were further limited by missing samples predominantly driven by lack of sample collection during the COVID-19 pandemic. The timing of immune analysis at day 15 may also be impacted by myelosuppression of temozolomide. Therefore, the immune exploratory analyses should be considered hypothesis generating. Given the single-arm combination nature of the trial, it is not possible to interpret the contribution of each drug to response or synergy of the combination therapy. Although the response rate observed in this study—especially in lung NEN—is higher than expected with either agent given alone, this combination warrants further study though to determine efficacy of temozolomide, nivolumab, or the combination.
In conclusion, combination nivolumab and temozolomide demonstrated promising efficacy in NENs, especially in patients with lung and pancreas NEN.”
(full study info referenced below)
Why is this trial important?
Immunotherapy does not have a good track record so far, particularly in well differentiated NETs. This trial was interesting because of the wide collection of NET types and although the conclusion favoured Lung and Pancreatic NETs.
Well differentiated NETs comprised 71% of the trial population and there was a 50/50 split between Grade 1/2 and 3.
It’s disappointing that only Lung and Pancreas showed favourable responses but this adds to the fact that NENs are a heterogenous grouping of cancers.
Read more here
1. ClinicalTrials.gov Identifier NCT03728361: Click here
2. Results summary. Cick here
What’s next?
It’s not clear, on paper the trial is no longer recruiting and the primary completion date has passed (31 Dec 2022). The study completion date is currently recorded as December 31, 2023.
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity. Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Finally
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Neuroendocrine Cancer – early diagnosis, not early misdiagnosis?
Orginal post – 25th Nov 2014. The papers and social media seem to be full of awareness and early diagnosis articles this month. This coincided
No Fear or Know Fear?
Edit: This article was written in 2015. Since then, I have moved to 12-month surveillance periods. I also changed the title as we are all
NET Syndromes – chicken or egg?
We’ve all heard the age-old question about the chicken and the egg? Scientists claimed to have ‘cracked’ the riddle of whether the chicken or the
Neuroendocrine Cancer: Fibrosis – an unsolved mystery?
What happened to me? Since I was diagnosed in 2010, I’ve always known about a fibrosis issue in my retroperitoneal area. It was identified on
Neuroendocrine Cancer – a difficult jigsaw
A few years ago, I received a request from a reader asking if I could write an article listing all the symptoms experienced by a
Neuroendocrine Cancer? – 10 questions to ask your doctor
On the day I was diagnosed, I hadn’t really thought about questions, the only one I actually remember asking was “how long do I have
Neuroendocrine Cancer: Beware But Be Aware
An awareness post from Ronny Allan BEWAREThere are a lot of scary diseases in this world. Take the lesser-known type of cancer that infiltrated my
Do you suffer from NET Brain?
A satirical look at the acronym or abbreviation “NET”. I wrote this after I noticed many non-NET people reading my blogs. The acronym ‘NET‘ (NeuroEndocrine
“You must be doing OK, you’ve not had chemotherapy”
If there’s a word which is synonymous with cancer, it’s chemotherapy. It’s what most people have in their mind when they are talking to a
Related
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts to your email.